Immunomodulatory pharmaceutical compositions and methods of use thereof
Provided are immunomodulatory pharmaceutical compositions that include alpha-synuclein, and at least one preselected antigen, such as at least one preselected peptide antigen or immunogen. Also provided are methods for modulating immune activity toward at least one preselected antigen in an at least substantially antigen-specific manner that includes administering such a composition to a human patient or a non-human mammalian subject.
1. An immunomodulatory pharmaceutical composition comprising:
(a) at least substantially pure alpha-synuclein protein; and
(b) at least one preselected antigen or immunogen, which is not a human or non-human mammalian alpha-synuclein protein or a fragment thereof.
2. The immunomodulatory pharmaceutical composition of claim 1 , further comprising at least partially purified human or non-human mammalian HLA protein or fragments thereof, wherein the at least one preselected antigen or immunogen does not comprise human or non-human mammalian HLA protein or fragments thereof.
3. The immunomodulatory pharmaceutical composition of claim 1 , wherein the at least one preselected antigen or immunogen comprises a synthetic peptide.
4. The immunomodulatory pharmaceutical composition of claim 1 , wherein the at least one preselected antigen or immunogen comprises an at least substantially purified protein.
5. The immunomodulatory pharmaceutical composition of claim 4 , wherein the at least substantially purified protein is a recombinant protein.
6. The immunomodulatory pharmaceutical composition of claim 1 , consisting essentially of:
(a) at least substantially pure alpha-synuclein protein; and
(b) at least one preselected antigen or immunogen, which is not a human or non-human mammalian alpha-synuclein protein or a fragment thereof.
7. The immunomodulatory pharmaceutical composition of claim 6 , wherein the at least one preselected antigen or immunogen comprises a synthetic peptide.
8. The immunomodulatory pharmaceutical composition of claim 6 , wherein the at least one preselected antigen or immunogen comprises an at least substantially purified protein.
9. The immunomodulatory pharmaceutical composition of claim 8 , wherein the at least substantially purified protein is a recombinant protein.
10. The immunomodulatory pharmaceutical composition of claim 1 , wherein the at least one preselected antigen or immunogen comprises a self-antigen of a human or non-human mammal.
11. The immunomodulatory pharmaceutical composition of claim 9 , wherein the self-antigen is associated with an autoimmune disease.
12. The immunomodulatory pharmaceutical composition of claim 1 , wherein the at least one preselected antigen or immunogen comprises a cancer-associated antigen or an antigen preferentially expressed on cancer cells versus normal cells of a human or non-human mammal.
13. The composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.
14. The composition of claim 1 , wherein the at least one preselected antigen or immunogen does not comprise human or non-human mammalian HLA protein or fragments thereof.
15. The composition of claim 6 , wherein the at least one preselected antigen or immunogen does not comprise human or non-human mammalian HLA protein or fragments thereof.
16. A method for modulating the immune response in a mammal to at least one preselected antigen comprising administering to a human or non-human mammal the immunomodulatory pharmaceutical composition of claim 1 .
17. A method for modulating the immune response in a mammal to at least one preselected antigen comprising administering to a human or non-human mammal the immunomodulatory pharmaceutical composition of claim 6 .
18. A method for manufacturing an immunomodulatory pharmaceutical composition comprising the steps of:
providing at least substantially purified human or non-human mammalian alpha-synuclein protein;
providing at least one preselected antigen or immunogen, which is not a human or non-human mammalian alpha-synuclein protein or a fragment thereof; and
mixing the at least substantially purified mammalian alpha-synuclein protein and the at least one preselected antigen or immunogen.
19. The method of claim 18 , wherein the at least one preselected antigen or immunogen comprises a synthetic peptide.
20. The method of claim 18 , wherein the at least one preselected antigen or immunogen comprises an at least substantially purified protein.
21. The method of claim 20 , wherein the at least substantially purified protein is a recombinant protein.
22. The method of claim 18 , wherein the at least substantially purified human or non-human mammalian alpha-synuclein protein comprises recombinant alpha-synuclein protein.
23. The method of claim 22 , wherein the at least one preselected antigen or immunogen comprises a synthetic peptide.
24. The method of claim 22 , wherein the at least one preselected antigen or immunogen comprises an at least substantially purified protein.
25. The method of claim 24 , wherein the at least substantially purified protein is a recombinant protein.
26. The method of claim 18 , further comprising the step of:
providing at least partially purified human or non-human mammalian HLA protein,
wherein said mixing step further comprises mixing the provided at least substantially pure alpha-synuclein protein, the at least one preselected antigen or immunogen, and the at least partially purified human or non-human mammalian HLA protein, and
wherein the at least one preselected antigen or immunogen is not a human or non-human mammalian HLA protein or fragment thereof.